Clinical Trials Logo

Diabete Mellitus clinical trials

View clinical trials related to Diabete Mellitus.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05752591 Completed - Hypogonadism Clinical Trials

Hypothalamic-pituitary Dysfunction in Diabetes

DIAPO
Start date: May 25, 2018
Phase:
Study type: Observational

Type 2 Diabetes mellitus (T2DM) is a chronic disease with a high prevalence and several comorbidities impacting on public health and society. Among the complications of T2DM it has been showed a high prevalence of hypogonadotropic hypogonadism. Even if hypogonadism is associated to a worse metabolic profile and cardiovascular risk, it is discussed whether and when to treat this potentially reversible form associated to diabetes. In fact, the pathogenic mechanism of this condition in diabetic patients is not fully understood, and its clinical correlates, including the prevalence of other possible associated hypothalamic-pituitary axes dysfunctioning, questioned. The aim of the present study is to assess with an observational, cross sectional study on a large series of type 2 diabetic patients, enrolled consecutively: all the suspected etiologies of this complication in one single evaluation (both acquired and genetic congenital predisposition), its clinical correlates and the real prevalence of the disease using the lastly validated criteria for late onset hypogonadotropic hypogonadism.

NCT ID: NCT05611944 Completed - Clinical trials for Surgical Site Infection

Irrigation and Suction Trial to Prevent SSI

I&S
Start date: April 1, 2017
Phase: N/A
Study type: Interventional

The study will be conducted on women with risk factors for SSI assigned to gynecological surgery with an open abdominal approach. The participants will be designated to either Irrigation and suction arm by bilateral drain insertion or the control arm by randomization through the parallel assignment. The participants will be followed for the outcome for four days in the hospital and then at 4 weeks, 8 weeks and 12 weeks postoperatively. The primary outcome measure will be the SSI rate. Secondary outcomes will be signs of SSI, post-operative pain, other complications and patient satisfaction.

NCT ID: NCT05251116 Completed - Diabete Mellitus Clinical Trials

Study of an Interstitial Fluid Glucose Sensor

Start date: December 11, 2021
Phase: N/A
Study type: Interventional

To characterize the System performance with respect to Yellow Springs Instrument (YSI) reference venous plasma measurements. Safety of the investigational device will be characterized by Adverse Device Effects and Serious Adverse Device Effects experienced by study participants.

NCT ID: NCT05144971 Completed - ESRD Clinical Trials

StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation

Start date: October 28, 2021
Phase:
Study type: Observational

The primary objective of this study is to assess the performance of the Nova StatStrip A Glucose/Creatinine Meter System in the hands of the subject (lay user) and compare the result to an accepted Glucose/Creatinine reference method in the hands of a trained technician.

NCT ID: NCT04864327 Completed - Smoking Cessation Clinical Trials

Smoking Intervention Among Patients With Diabetes

Start date: May 5, 2011
Phase: N/A
Study type: Interventional

This study determined the prevalence of tobacco smoking among patients with diabetes and evaluated the impact of a diabetes-specific tobacco cessation intervention on tobacco cessation outcomes and on the glycaemic control, blood pressure, lipid profile, complications, comorbidities and number of cigarettes consumed per day among the patients.

NCT ID: NCT04409171 Completed - Diabete Mellitus Clinical Trials

Glucose Metabolism After Partial Pancreatectomy

Start date: September 1, 2015
Phase:
Study type: Observational [Patient Registry]

This is a single center observational study to assess alteration of glucose metabolism after pancreatectomy.

NCT ID: NCT04407182 Completed - Covid-19 Clinical Trials

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

Start date: May 4, 2020
Phase: Phase 2
Study type: Interventional

This is a two-arm, open-label, randomized, phase 2, controlled center study to assess the safety and efficacy of Viusid and Asbrip in patients with mild to moderate symptoms of respiratory disease caused by 2019 coronavirus infection. Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally. A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care and 20 control patients with standard of care. Treatment duration: 21 days.

NCT ID: NCT04245982 Completed - Periodontitis Clinical Trials

PPAR, RXR, and VDR Expressions in Diabetes

Start date: January 1, 2019
Phase:
Study type: Observational

Objective: Diabetes and periodontitis are two chronic inflammatory diseases sharing specific etiopathogenetic mechanisms, and both cause severe inflammation and destruction. The aim of the present study was to determine the receptor expressions of Peroxisome proliferative-activated receptor (PPAR)-γ, Retinoid X receptor (RXR)-α, Vitamin D receptor (VDR), and nuclear factor kappa B (NF-κB) expressions in healthy gingiva and diseased gingival samples with diabetes. Methods: 45 participants as 1; healthy controls (C), 2; periodontitis group (P), and 3; diabetes and periodontitis group (DP) were enrolled. Plaque index (PI), gingival index (GI) and clinical attachment levels (CAL) were recorded in all participants. Two gingival biopsies from each participant were obtained, and one underwent histological tissue processing while the other underwent RT-PCR analysis of nuclear receptors. Inflammatory and fibroblast cell counts, PPAR-γ, RXR-α, and VDR were evaluated. Results: Fibroblast cells were lowest in the DP group and highest in the healthy group. PPAR-γ, VDR, RXR, and NF-κB expressions were higher in the healthy controls in the RT-PCR analysis and similar in the other groups. Immunohistochemistry analysis also showed similar results. Conclusion: Results concluded that healthy gingival samples had higher PPAR-γ, RXR, VDR, and NF-κB expressions, and the immunohistochemistry results also supported this finding. The healthy gingiva contained higher fibroblast cells and lower inflammatory cells.

NCT ID: NCT03953092 Completed - Diabete Mellitus Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple ascending oral dose administration.

NCT ID: NCT03934281 Completed - Amputation Clinical Trials

Study of the Value of Using a Honey Dressing Compared to the Use of a Standard Dressing on the Toe Amputation Wound in the Diabetic Patient

MELIDIAB
Start date: June 27, 2018
Phase: N/A
Study type: Interventional

Numerous scientific publications in France and internationally have described the healing, anti-bacterial, anti-oxidant, anti-inflammatory and immuno-modulating properties of honey. Honey is effective in the management of many infected or uninfected post-surgical wounds. This study focuses on post surgical wounds after toe amputation in diabetic patients. The main objective of this study is to compare the rate of epidermisation at six months for these wounds, between honey dressing and other dressing devices used according to the french Haute Autorité de Santé (HAS) recommendations